How to Buy Supriya Lifescience Ltd Shares?
You can easily buy the stocks/shares of Supriya Lifescience Ltd (SUPRIYA) on Tickertape or through broker platform by opening a Demat & Trading account onlineWhat is the Share Price of Supriya Lifescience Ltd?
The stock prices are volatile and keep changing through the day depending upon various factors and market conditions. The Share price of SUPRIYA as on 15th May 2025 is ₹697.51What is the return on Supriya Lifescience Ltd share?
The past returns of Supriya Lifescience Ltd (SUPRIYA) share are- Past 1 week: N/A
- Past 1 month: -81.04
- Past 3 months: 15.42
- Past 6 months: -6.53
- Past 1 year: 79.57
- Past 3 years: 106.95
- Past 5 years: 76.42
What is the Dividend yield % on Supriya Lifescience Ltd share?
The current dividend yield of Supriya Lifescience Ltd (SUPRIYA) is 0.15What is the Market Cap of Supriya Lifescience Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Supriya Lifescience Ltd (SUPRIYA) is ₹5542.36Cr as of 15th May 2025What is the 52 Week High and Low of Supriya Lifescience Ltd?
The 52-week high and low of Supriya Lifescience Ltd (SUPRIYA) is ₹842 and ₹368.What is the PE and PB ratio of Supriya Lifescience Ltd?
The P/E (price-to-earnings) and P/B (price-to-book) ratios of Supriya Lifescience Ltd are 29.49 and 6.80 respectively.Which sector does Supriya Lifescience Ltd belong to?
Supriya Lifescience Ltd (SUPRIYA) belongs to the Health Care sector & Pharmaceuticals sub-sector.What are the peers or stocks similar to Supriya Lifescience Ltd?
The peers or stocks similar to Supriya Lifescience Ltd are: and many others.Can't decide whether or not to buy Supriya Lifescience Ltd?
Worry no more! Login to Tickertape and check out Supriya Lifescience Ltd (SUPRIYA) scorecard & all the relevant insights today5. Test Stocks FAQ What is the 52 Week High and Low of Supriya Lifescience Ltd?
The 52-week high and low of Supriya Lifescience Ltd (SUPRIYA) is ₹842 and ₹368.1. Test Stocks FAQ for Supriya Lifescience Ltd Shares?
You can easily buy the stocks/shares of Supriya Lifescience Ltd (SUPRIYA) on Tickertape or through broker platform by opening a Google & Trading account online3. Test Stocks FAQ What is the Share Price of Supriya Lifescience Ltd?
The stock prices are volatile and keep changing through the day depending upon various factors and market conditions. The Share price of SUPRIYA as on 15th May 2025 is ₹697.51
Supriya Lifescience Ltd
SUPRIYA Share Price
697.511.67% (+11.46)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
How to use scorecard? Learn more
SUPRIYA Performance & Key Metrics
SUPRIYA Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 29.49 | 6.80 | 0.15% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.21 | 6.66 | 0.83% |
SUPRIYA Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
SUPRIYA Company Profile
Supriya Lifescience is a manufacturer of pharmaceutical preparation.
SUNPHARMA
PE Ratio
37.00
37.00
1Y Return
11.72%
11.72%
Buy Reco %
89.19
89.19
CIPLA
PE Ratio
23.03
23.03
1Y Return
2.55%
2.55%
Buy Reco %
71.05
71.05
DRREDDY
PE Ratio
20.02
20.02
1Y Return
11.76%
11.76%
Buy Reco %
82.05
82.05
TORNTPHARM
PE Ratio
57.53
57.53
1Y Return
13.13%
13.13%
Buy Reco %
67.74
67.74
MANKIND
PE Ratio
49.29
49.29
1Y Return
6.30%
6.30%
Buy Reco %
—
—
SUPRIYA Sentiment Analysis
SUPRIYA Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
SUPRIYA Stock Summary · January 2025
Company is navigating a complex landscape characterized by declining market share in deposits, challenges in meeting Priority Sector Lending (PSL) obligations, and fluctuations in current account flows. Despite these hurdles, the bank is focusing on enhancing customer engagement and service delivery to drive deposit growth, with recent monthly inflows showing a positive trend. The management emphasizes a strategic approach to maintaining profitability over aggressive expansion, particularly in light of competitive pressures and a tight liquidity environment. Efforts to improve operational efficiencies through digitization and a commitment to stable cost management are underway, alongside a proactive strategy to reduce borrowings and strengthen the balance sheet. Overall, while facing short-term challenges, the bank remains optimistic about future performance and is committed to achieving sustainable growth through strategic investments and improved customer outreach.
SUPRIYA Stock Growth Drivers
SUPRIYA Stock Growth Drivers
1Focus on Sustainable Growth
Company is prioritizing profitable growth over mere expansion, emphasizing a strategy that encourages ground-level teams
SUPRIYA Stock Challenges
SUPRIYA Stock Challenges
5Deposit Growth Shortfalls
The company has experienced deposit growth that has not met expectations, attributed to seasonal trends
Loan Growth Concerns
There is uncertainty regarding the company's loan deposit ratio (LDR) and its implications for loan
SUPRIYA Forecast
What are forecasts?
What are forecasts?
Forecasting uses historical data as inputs to make informed predictive estimates determining the direction of future trends. Price, revenue & earnings forecasts represent where the stock level, business prospects and profits are potentially expected to be at the end of the forecast period
SUPRIYA Forecasts
Price
Revenue
Earnings
SUPRIYA Share Price Forecast
SUPRIYA Share Price Forecast
2025
Current
₹689.55
Baseline
Forecast for Jun 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹689.55
Baseline
Forecast for Jun 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
SUPRIYA Company Revenue Forecast
SUPRIYA Company Revenue Forecast
2025
Current
₹706.30
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ cr.
2025
Current
₹706.30
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ cr.
SUPRIYA Stock EPS (Earnings Per Share) Forecast
SUPRIYA Stock EPS (Earnings Per Share) Forecast
2025
Current
₹23.35
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹23.35
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
SUPRIYA
SUPRIYA
Income
Balance Sheet
Cash Flow
Annual Normal View
SUPRIYA Income Statement
SUPRIYA Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 190.95 | 221.51 | 285.86 | 322.71 | 396.22 | 537.63 | 470.43 | 581.01 | 706.30 | 706.30 | ||||||||||
Raw Materials | 112.46 | 127.94 | 146.07 | 152.38 | 140.57 | 198.83 | 187.32 | 191.43 | 435.69 | 435.71 | ||||||||||
| Power & Fuel Cost | 6.93 | 7.03 | 0.00 | 8.97 | 9.24 | 14.07 | 20.95 | 21.37 | ||||||||||||
| Employee Cost | 15.49 | 16.30 | 0.00 | 18.88 | 32.76 | 49.08 | 55.58 | 67.64 | ||||||||||||
| Selling & Administrative Expenses | 8.11 | 15.85 | 0.00 | 30.10 | 31.88 | 33.83 | 37.32 | 39.43 | ||||||||||||
| Operating & Other expenses | 23.39 | 23.84 | 67.03 | 2.92 | 3.62 | 20.25 | 30.87 | 74.48 | ||||||||||||
EBITDA | 24.57 | 30.55 | 72.76 | 109.46 | 178.15 | 221.57 | 138.39 | 186.66 | 270.61 | 270.59 | ||||||||||
| Depreciation/Amortization | 4.75 | 5.33 | 5.44 | 6.41 | 6.76 | 10.12 | 11.82 | 15.81 | 20.44 | 20.44 | ||||||||||
| PBIT | 19.82 | 25.22 | 67.32 | 103.05 | 171.39 | 211.45 | 126.57 | 170.85 | 250.17 | 250.15 | ||||||||||
| Interest & Other Items | 11.76 | 10.75 | 10.22 | 6.85 | 4.08 | 4.20 | 3.08 | 5.15 | 1.69 | 1.70 | ||||||||||
| PBT | 8.06 | 14.47 | 57.10 | 96.20 | 167.31 | 207.25 | 123.49 | 165.70 | 248.48 | 248.45 | ||||||||||
| Taxes & Other Items | 2.40 | 5.74 | 17.68 | 22.84 | 43.71 | 55.44 | 33.63 | 46.58 | 60.53 | 60.53 | ||||||||||
| Net Income | 5.66 | 8.73 | 39.42 | 73.36 | 123.60 | 151.81 | 89.86 | 119.12 | 187.95 | 187.92 | ||||||||||
| EPS | 0.77 | 1.19 | 5.39 | 10.02 | 16.89 | 19.76 | 11.17 | 14.80 | 23.35 | 23.35 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 2.00 | 0.54 | 0.60 | 0.60 | 0.80 | 1.00 | 0.80 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.20 | 0.03 | 0.03 | 0.05 | 0.05 | 0.04 | 0.03 |
SUPRIYA Company Updates
FY 2025FY 2025
Investor Presentation
May 27PDF
Jan 24PDF
SUPRIYA Stock Peers
What are peers and why compare against them?
What are peers and why compare against them?
A stock's peers are companies which have similar business interests, operations and belong to the same industry sector. Comparing various metrics against peers can give valuable insights on whether the company's stock is over/under-valued and the company's growth outlook vs the industry as a whole
SUPRIYA Past Performance & Peer Comparison
SUPRIYA Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation-basic on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Supriya Lifescience Ltd | 29.49 | 6.80 | 0.15% |
| Sun Pharmaceutical Industries Ltd | 37.00 | 6.03 | 0.95% |
| Cipla Ltd | 23.03 | 4.53 | 1.06% |
| Dr Reddy's Laboratories Ltd | 20.02 | 4.01 | 0.59% |
SUPRIYA Stock Price Comparison
Compare SUPRIYA with any stock or ETFCompare SUPRIYA with any stock or ETF
SUPRIYA
SUPRIYA Holdings
SUPRIYA Shareholdings
What are shareholdings?
What are shareholdings?
Apart from retail investors, a company’s shares are held by promoters, foreign & domestic institutions (large investors) and mutual funds. Promoters are the ship captains and control the company’s direction. Along with institutional and mutual fund holdings, a change in their holdings can indicate performance outlook for the stock
SUPRIYA Promoter Holdings Trend
SUPRIYA Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
SUPRIYA Institutional Holdings Trend
SUPRIYA Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
SUPRIYA Shareholding Pattern
SUPRIYA Shareholding Pattern
SUPRIYA Shareholding History
SUPRIYA Shareholding History
Foreign Institutions
Mutual Funds Invested in SUPRIYA
Mutual Funds Invested in SUPRIYA
No mutual funds holding trends are available
Top 5 Mutual Funds holding Supriya Lifescience Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.1235% | Percentage of the fund’s portfolio invested in the stock 1.78% | Change in the portfolio weight of the stock over the last 3 months 1.78% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 17/71 (+25) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0878% | Percentage of the fund’s portfolio invested in the stock 1.51% | Change in the portfolio weight of the stock over the last 3 months 1.51% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 19/69 (+24) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0757% | Percentage of the fund’s portfolio invested in the stock 1.27% | Change in the portfolio weight of the stock over the last 3 months 1.27% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 26/51 (+1) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing SUPRIYA stock
smallcases containing SUPRIYA stock
Looks like this stock is not in any smallcase yet.
SUPRIYA Events
SUPRIYA Events
SUPRIYA Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
SUPRIYA has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.15%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.45 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
What are dividends?
What are dividends?
Dividends are a portion of earnings that a company distributes to all its shareholders every year. Dividend return is one of the most important things to be considered while investing for long term. It’s the additional return on top of what investors earn through price appreciation
SUPRIYA Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
SUPRIYA has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.15%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.45 every year
SUPRIYA Upcoming Dividends
SUPRIYA Upcoming Dividends
No upcoming dividends are available
SUPRIYA Past Dividends
SUPRIYA Past Dividends
Cash Dividend
Ex DateEx DateSep 20, 2024
Final
Final | Div/Share: ₹0.80
Dividend/Share
₹0.80
Ex DateEx Date
Sep 20, 2024
Cash Dividend
Ex DateEx DateSep 14, 2023
Final
Final | Div/Share: ₹0.60
Dividend/Share
₹0.60
Ex DateEx Date
Sep 14, 2023
Cash Dividend
Ex DateEx DateSep 1, 2022
Final
Final | Div/Share: ₹0.60
Dividend/Share
₹0.60
Ex DateEx Date
Sep 1, 2022
SUPRIYA Stock News & Opinions
SUPRIYA Stock News & Opinions
Articles & Videos
Earnings
Supriya Lifescience standalone net profit rises 36.42% in the March 2025 quarter
Net profit of Supriya Lifescience rose 36.42% to Rs 50.38 crore in the quarter ended March 2025 as against Rs 36.93 crore during the previous quarter ended March 2024. Sales rose 16.39% to Rs 184.11 crore in the quarter ended March 2025 as against Rs 158.18 crore during the previous quarter ended March 2024. For the full year,net profit rose 57.80% to Rs 187.96 crore in the year ended March 2025 as against Rs 119.11 crore during the previous year ended March 2024. Sales rose 22.11% to Rs 696.49 crore in the year ended March 2025 as against Rs 570.37 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales184.11158.18 16 696.49570.37 22 OPM %36.7135.08 -37.4430.33 - PBDT70.1457.08 23 268.93181.50 48 PBT64.0653.17 20 248.49165.69 50 NP50.3836.93 36 187.96119.11 58 Powered by Capital Market - Live
2 weeks agoCapital Market - Live
Corporate
Board of Supriya Lifesciences recommends final dividend
Supriya Lifesciences announced that the Board of Directors of the Company at its meeting held on 27 May 2025, inter alia, have recommended the final dividend of Rs 1 per equity Share (i.e. 50%) , subject to the approval of the shareholders.Powered by Capital Market - Live
2 weeks agoCapital Market - Live
Corporate
Supriya Lifesciences to announce Quarterly Result
Supriya Lifesciences will hold a meeting of the Board of Directors of the Company on 27 May 2025.Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
Board of Supriya Lifescience appoints company secretary and compliance officer
The Board of Supriya Lifescience at its meeting held on 10 March 2025 has approved the appointment of Prachi Sathe bearing Membership No. A-70252 as Company Secretary and Compliance Officer of the Company with effect from 10 March 2025. Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Supriya Lifesciences to hold board meeting
Supriya Lifesciences will hold a meeting of the Board of Directors of the Company on 10 March 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Supriya Lifescience standalone net profit rises 57.03% in the December 2024 quarter
Net profit of Supriya Lifescience rose 57.03% to Rs 46.78 crore in the quarter ended December 2024 as against Rs 29.79 crore during the previous quarter ended December 2023. Sales rose 32.54% to Rs 185.65 crore in the quarter ended December 2024 as against Rs 140.07 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales185.65140.07 33 OPM %35.5229.62 - PBDT67.5444.07 53 PBT62.5840.11 56 NP46.7829.79 57 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Supriya Lifesciences declare Quarterly Result
Supriya Lifesciences will hold a meeting of the Board of Directors of the Company on 24 January 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Spotlight
Supriya Life gains after bagging approval from ANVISA for Esketamine Hydrochloride
Esketamine hydrochloride is a vital drug to be used for treating mental illness and is likely to significantly impact the LATAM market. This approval will enable the company to provide high-quality healthcare solutions in a market where demand for novel, reasonably priced drugs is growing. The company said that it is the first firm in Brazil to have received regulatory permission for this highly specialised pharmaceutical. Moreover, the business submitted a ground-breaking patent application for an enhanced, low-cost method of atorvastatin synthesis. Global healthcare relies heavily on atorvastatin, a key treatment for controlling cholesterol and preventing cardiovascular disease, and this achievement shows Supriya's dedication to drug cost and raising accessibility. This ground-breaking technique makes drugs more affordable for patients by increasing their efficacy while reducing production costs. Satish Wagh, executive chairman and whole time director, Supriya Lifescience, stated, Our commitment to transforming pharmaceutical manufacturing while maintaining affordability is demonstrated by our invention in the synthesis of atorvastatin. Our global presence is strengthened by the CADIFA approval, which also allows us to introduce cutting-edge therapies like Esketamine Hydrochloride in important foreign countries, starting with Brazil. Supriya Lifesciences is primarily engaged in manufacturing of Bulk drugs and pharmaceutical chemicals. The company's standalone net profit jumped 93.3% to Rs 46.15 crore in Q2 FY25 as compared with Rs 23.88 crore in Q2 FY24. Net sales increased 18.6% YoY to Rs 166.10 crore in Q2 FY25.Powered by Capital Market - Live
6 months agoCapital Market - Live
Earnings
Supriya Lifescience standalone net profit rises 93.26% in the September 2024 quarter
Net profit of Supriya Lifescience rose 93.26% to Rs 46.15 crore in the quarter ended September 2024 as against Rs 23.88 crore during the previous quarter ended September 2023. Sales rose 18.56% to Rs 166.10 crore in the quarter ended September 2024 as against Rs 140.10 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales166.10140.10 19 OPM %38.9622.66 - PBDT66.8133.76 98 PBT62.0729.78 108 NP46.1523.88 93 Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Supriya Lifesciences to hold AGM
Supriya Lifesciences announced that the Annual General Meeting (AGM) of the company will be held on 27 September 2024.Powered by Capital Market - Live
9 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 15.24%, vs industry avg of 9.02%
Over the last 5 years, market share increased from 0.07% to 0.15%
Over the last 5 years, net income has grown at a yearly rate of 24.75%, vs industry avg of 15.29%